XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate efficacy and safety of Capecitabine/Cisplatin for
gastric cancer patients who relapsed after adjuvant chemotherapy by S-1.
Phase:
Phase 2
Details
Lead Sponsor:
Epidemiological and Clinical Research Information Network